← All Sponsors

SPONSOR

Sheng-Li Xue, MD

Total Trials

1

Recruiting

1

Phases

Phase 2

Conditions studied: ALL MRD-positive Hematopoietic Stem Cell Transplantation

NCT05940961 Phase 2

Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL